Management of hypertension, alone or in combination with other antihypertensive agents. Not indicated for the treatment of hypertensive emergencies.
Angina
Management of chronic stable angina pectoris.
A component of the standard therapeutic measures in the management of unstable angina or non-ST-segment elevation/non-Q-wave MI†.
Supraventricular Tachyarrhythmias
β-Adrenergic blocking agents, including propranolol, are one of several preferred antiarrhythmic agents for the treatment of stable, narrow-complex supraventricular tachycardias (e.g., paroxysmal supraventricular tachycardia [reentry supraventricular tachycardia], ectopic or multifocal atrial tachycardia, junctional tachycardia) if the rhythm is not controlled by vagal maneuvers or adenosine in patients with preserved left ventricular function and for rate control in atrial fibrillation or flutter in patients with preserved left ventricular function.
Treatment of persistent atrial extrasystoles and noncompensatory sinus tachycardia that impair the well-being of the patient and do not respond to conventional therapy.
May be especially useful in conjunction with a cardiac glycoside to slow ventricular rates in the treatment of atrial flutter and fibrillation in patients whose arrhythmia is not controlled by adequate doses of a cardiac glycoside alone.
Ventricular Arrhythmias
Treatment of tachyarrhythmias during cardiovascular surgery†, including decreasing ventricular fibrillation time during cardiopulmonary bypass surgery†.
Treatment of persistent ventricular premature contractions that impair the well-being of the patient and do not respond to conventional therapy.
Tachyarrhythmias Associated with Cardiac Glycoside Intoxication or Catecholamine Excess
Management of supraventricular or ventricular tachyarrhythmias associated with cardiac glycoside toxicity when AV block is not present.
Management of resistant tachyarrhythmias associated with catecholamine excess during anesthesia; use with extreme caution and constant ECG and central venous pressure monitoring. More effective and less hazardous therapy, such as lessening the depth of anesthesia or improving ventilation, is preferred.
Hypertrophic Subaortic Stenosis
Management of exertional or other stress-induced angina, vertigo, syncope, and palpitation in patients with hypertrophic subaortic stenosis; clinical improvement may be temporary.
Pheochromocytoma
Management of symptoms resulting from excessive β-receptor stimulation in patients with inoperable or metastatic pheochromocytoma, as an adjunct to α-adrenergic blocking agents. Initiate therapy with an α-adrenergic blocking agent prior to treatment of pheochromocytoma. (See Pheochromocytoma under Cautions.)
Management of tachycardia prior to or during surgery in patients with pheochromocytoma, as an adjunct to α-adrenergic blocking agents. Initiate therapy with an α-adrenergic blocking agent prior to treatment of pheochromocytoma. (See Pheochromocytoma under Cautions.)
Thyrotoxicosis
Short-term (2–4 weeks) adjunctive therapy of tachycardia and supraventricular arrhythmias in patients with thyrotoxicosis when these symptoms are distressful or hazardous, or when immediate therapy is necessary.
Vascular Headache
Prophylaxis of common migraine headache; not recommended for the treatment of a migraine attack that has already started.
AMI
Secondary prevention following AMI to reduce the risk of reinfarction† and mortality.
Management of ventricular arrhythmias complicating AMI.
Essential Tremor
Management of essential (familial, hereditary) tremor.
Not indicated for tremor associated with Parkinsonism.
Media Gallery
Drug Info Tools
